ESSA Pharma (EPIX) Competitors $1.74 +0.04 (+2.06%) As of 07/3/2025 01:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPIX vs. LFCR, AARD, OLMA, LIMN, OCGN, ZYBT, GOSS, GLUE, CRVS, and RNACShould you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include Lifecore Biomedical (LFCR), Aardvark Therapeutics (AARD), Olema Pharmaceuticals (OLMA), Liminatus Pharma (LIMN), Ocugen (OCGN), Zhengye Biotechnology (ZYBT), Gossamer Bio (GOSS), Monte Rosa Therapeutics (GLUE), Corvus Pharmaceuticals (CRVS), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical products" industry. ESSA Pharma vs. Its Competitors Lifecore Biomedical Aardvark Therapeutics Olema Pharmaceuticals Liminatus Pharma Ocugen Zhengye Biotechnology Gossamer Bio Monte Rosa Therapeutics Corvus Pharmaceuticals Cartesian Therapeutics Lifecore Biomedical (NASDAQ:LFCR) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations. Is LFCR or EPIX more profitable? ESSA Pharma has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -35.90%. ESSA Pharma's return on equity of -23.48% beat Lifecore Biomedical's return on equity.Company Net Margins Return on Equity Return on Assets Lifecore Biomedical-35.90% -551.09% -13.89% ESSA Pharma N/A -23.48%-22.86% Does the media refer more to LFCR or EPIX? In the previous week, ESSA Pharma had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 1 mentions for ESSA Pharma and 0 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.00 equaled ESSA Pharma'saverage media sentiment score. Company Overall Sentiment Lifecore Biomedical Neutral ESSA Pharma Neutral Which has better earnings and valuation, LFCR or EPIX? Lifecore Biomedical has higher revenue and earnings than ESSA Pharma. Lifecore Biomedical is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifecore Biomedical$128.26M2.32$12.01M-$1.45-5.54ESSA PharmaN/AN/A-$28.54M-$0.63-2.75 Do insiders & institutionals hold more shares of LFCR or EPIX? 83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are owned by institutional investors. 32.2% of Lifecore Biomedical shares are owned by insiders. Comparatively, 15.5% of ESSA Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, LFCR or EPIX? Lifecore Biomedical has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Do analysts prefer LFCR or EPIX? Lifecore Biomedical presently has a consensus price target of $8.00, suggesting a potential downside of 0.37%. ESSA Pharma has a consensus price target of $2.00, suggesting a potential upside of 15.27%. Given ESSA Pharma's higher possible upside, analysts plainly believe ESSA Pharma is more favorable than Lifecore Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifecore Biomedical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50ESSA Pharma 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryLifecore Biomedical and ESSA Pharma tied by winning 7 of the 14 factors compared between the two stocks. Get ESSA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPIX vs. The Competition Export to ExcelMetricESSA PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.24M$2.43B$5.53B$9.05BDividend YieldN/A1.78%5.24%4.03%P/E Ratio-2.758.9827.5220.22Price / SalesN/A682.84421.02118.64Price / CashN/A158.5936.8958.07Price / Book0.624.588.045.67Net Income-$28.54M$31.34M$3.18B$249.13M7 Day Performance0.29%3.25%2.82%3.30%1 Month Performance1.46%6.80%3.70%5.20%1 Year Performance-63.70%1.89%35.41%21.38% ESSA Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPIXESSA Pharma1.3226 of 5 stars$1.74+2.1%$2.00+15.3%-63.7%$77.24MN/A-2.7550News CoverageLFCRLifecore Biomedical1.0508 of 5 stars$8.12-0.9%$8.00-1.5%+62.9%$300.68M$128.26M-5.60690High Trading VolumeAARDAardvark TherapeuticsN/A$13.52+1.0%$33.00+144.1%N/A$293.38MN/A0.0018Analyst RevisionGap UpOLMAOlema Pharmaceuticals1.7576 of 5 stars$4.26-7.8%$24.50+475.1%-58.8%$291.47MN/A-2.1270Positive NewsLIMNLiminatus PharmaN/A$11.15+17.6%N/AN/A$290.01MN/A0.00N/AGap UpOCGNOcugen1.0196 of 5 stars$0.97-1.4%$6.00+518.3%-41.1%$283.39M$4.05M-5.1180High Trading VolumeZYBTZhengye BiotechnologyN/A$5.97-9.7%N/AN/A$281.61MN/A0.00278News CoverageLockup ExpirationGap DownGOSSGossamer Bio3.7798 of 5 stars$1.23-1.6%$7.33+496.2%+18.9%$279.58M$114.70M-5.35180GLUEMonte Rosa Therapeutics1.3753 of 5 stars$4.51-2.0%$15.33+240.0%+29.7%$277.41M$75.62M56.3890News CoverageCRVSCorvus Pharmaceuticals2.4882 of 5 stars$4.00+2.8%$15.00+275.0%+121.1%$272.68MN/A-4.0830Positive NewsInsider TradeRNACCartesian Therapeutics1.4476 of 5 stars$10.39-2.7%$41.25+297.0%-36.6%$269.66M$34.17M-0.2064 Related Companies and Tools Related Companies Lifecore Biomedical Alternatives Aardvark Therapeutics Alternatives Olema Pharmaceuticals Alternatives Liminatus Pharma Alternatives Ocugen Alternatives Zhengye Biotechnology Alternatives Gossamer Bio Alternatives Monte Rosa Therapeutics Alternatives Corvus Pharmaceuticals Alternatives Cartesian Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPIX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.